Page last updated: 2024-12-06

ortho-cept

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethinyl estradiol-desogestrel combination: Ethinyl Estradiol and Desogestrell given in fixed proportions; has proved to be an effective & well-tolerated oral contraceptive, which improves cycle control & has a beneficial effect on acne [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62957
CHEMBL ID1697756
SCHEMBL ID1649231
MeSH IDM0106670

Synonyms (47)

Synonym
ortho-cept
marvelon
kariva
desogestrel and ethinyl estradiol
cyclessa
desogestrel; ethinyl estradiol
ctr-24
ctr 24
19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-, mixt. with (17alpha)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol
mercilon
practil 21
71138-35-7
varnoline
desogen (contraceptive)
combiphasic ee-dsg contraceptive
oviol
ovidol
ethinyl estradiol-desogestrel combination
CHEMBL1697756
orthocept
caziant
relivon
securgin
ortho cept
ethinyl estradiol and desogestrel
ethinylestradiol - desogestrel mixt.
emoquette
velivet
novelon
kalliga
cycleane
cesia
marvelone
laurina
gracial
kimidess
desogestrel; ethinyl
desogestrel - ethynylestradiol mixt.
desolett
org 5187
apri
reclipsen
lovelle
desogestrel - ethinylestradiol mixt.
bekyree
SCHEMBL1649231
DTXSID20221336

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The side effect profile was favourable."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
" These findings show that the new OC has very good cycle control and a agreeable side effect profile."( Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Coelingh Bennink, HJ; Dieben, TO; op ten Berg, MT, 1994
)
0.29
"6% of all subjects reported one or more adverse events, and a total of 43."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
"The study confirmed that Mircette is a safe and efficacious oral contraceptive that is well tolerated and acceptable to women who have previously used oral contraceptives, as well as first-time users."( An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (27.91)18.7374
1990's14 (32.56)18.2507
2000's5 (11.63)29.6817
2010's12 (27.91)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.01 (24.57)
Research Supply Index4.28 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index48.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (57.78%)5.53%
Reviews1 (2.22%)6.00%
Case Studies2 (4.44%)4.05%
Observational1 (2.22%)0.25%
Other15 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]